Up next

2026: Drugs To Watch: The Year Ahead

Matthew Arnold, Principal Analyst and Content Strategist, Clarivate

Which bio/pharmaceuticals, slated to be launched or approved in 2026, may be potential blockbusters or are raising the innovation bar to new heights? Matthew Arnold, Principal Analyst and Content Strategist, Clarivate, highlights the 11 drugs making Clarivate’s Drugs to Watch list in 2026, key trends in product innovation, and the companies and products on the industry’s radar.

Each episode of the Production to Prescription podcast is housed on the DCAT Value Chain Insights website and also delivered through DCAT Value Chain Insights weekly email digest. Not a subscriber? Click here to subscribe to DCAT Value Chain Insights, or get each episode through: 

For a full list of the 2026 podcast episode schedule, click here.

You May Also Like

New Excipient Products: Are They Coming?

By
Innovation in excipients is important to optimize a drug formulation, but there are barriers to innovation, including regulatory barriers, which excipient manufacturers and users are seeking to address. Providing the…

Pipeline Potential: Small-Molecule Drugs

By
New drug classes–proteolysis-targeting chimeras (PROTACs) and molecular glue degraders–are potentially a new source of product innovation for small-molecule drugs in their ability to reach previously “undruggable” drug targets. There have…

CDMO Outlook: Small Molecules—What Lies Ahead?

By
Sponsored by Vetter As the industry reaches the mid-point in 2026, how are CDMOs of small-molecule drugs faring? The larger scale CDMOs with late-phase and/or commercial-scale capabilities are faring well…

A CDMO Roundtable: The Making of a Molecule: Peptide Synthesis

By
The blockbuster success of the GLP-1 agonists and related drugs has renewed interest in peptide-based drugs, but how is the manufacturing technology evolving? In a CDMO roundtable, industry experts share…